LANDA, Leoš, Michal JURAJDA and Alexandra ŠULCOVÁ. Altered dopamine D1 and D2 receptor mRNA expression in mesencephalon from mice exposed to repeated treatments with methamphetamine and cannabinoid CB1 agonist methanandamide. Neuroendocrinology Letters. Stockholm: MAGHIRA & MAAS PUBLICATIONS, vol. 33, No 4, p. 446-452. ISSN 0172-780X. 2012.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Altered dopamine D1 and D2 receptor mRNA expression in mesencephalon from mice exposed to repeated treatments with methamphetamine and cannabinoid CB1 agonist methanandamide
Authors LANDA, Leoš (203 Czech Republic), Michal JURAJDA (203 Czech Republic, belonging to the institution) and Alexandra ŠULCOVÁ (203 Czech Republic, guarantor, belonging to the institution).
Edition Neuroendocrinology Letters, Stockholm, MAGHIRA & MAAS PUBLICATIONS, 2012, 0172-780X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30000 3. Medical and Health Sciences
Country of publisher Sweden
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 0.932
RIV identification code RIV/00216224:14740/12:00061208
Organization unit Central European Institute of Technology
UT WoS 000310259500015
Keywords in English behavioural sensitization; methamphetamine; methanandamide; D1 and D2 receptor mRNA expression; mouse mesencephalon
Tags ok, rivok
Tags International impact, Reviewed
Changed by Changed by: Olga Křížová, učo 56639. Changed: 8/4/2013 06:10.
Abstract
OBJECTIVES: In our previous studies we found that both acute administration of CB1 receptor agonist methanandamide and repeated methanandamide pretreatment prior to methamphetamine challenge dose elicited increase in the CB1 receptor mRNA expression in the mouse mesencephalon. As a reciprocal cross-talk is reported between the cannabinoid CB1 and dopamine receptors, that are highly co-localized on brain neurones, we targeted possible changes in relative expression of dopamine D1 and D2 receptor mRNA in mesencephalon in mice sensitized by repeated treatments to methamphetamine stimulatory effects and cross-sensitized to methamphetamine by cannabinoid CB1 receptor agonist methanandamide pre-treatment. METHODS: To confirm development of behavioural sensitization or cross-sensitization, respectively, we observed changes in locomotion using the open field test. Mice were treated repeatedly with either methamphetamine or methamphetamine after repeated pre-treatment with methanandamide. After each measurement of locomotion one third of animals were sacrificed and the brain was stored. RNA was isolated from the midbrain and used for reverse transcription and subsequent real-time PCR. RESULTS AND CONCLUSION: As in many of our earlier studies with the same dosage regimen we found in the behavioural part both development of sensitization to methamphetamine stimulatory effects after repeated treatment and crosssensitization to them by pre-treatment with cannabinoid receptor CB1 agonist methanandamide. Real-time PCR analyses showed an increase in D1 receptor mRNA expression after the first dose of methamphetamine (that persisted also after the last dose of methamphetamine) and after the first dose of methanandamide (which also persisted after the methamphetamine challenge dose).
Links
ED1.1.00/02.0068, research and development projectName: CEITEC - central european institute of technology
PrintDisplayed: 29/3/2024 02:07